IL17A and COVID-19: Several other clinical trials in hospitalized COVID-19 patients have also revealed the immunomodulatory (anti-inflammatory) effects of curcumin therapy, including reduction in the serum levels of IL-1β, IL-6, INF-γ, TNF-α, IL-17, IL-10, IL-35, TGF-β, PCT, FoxP3, IL-10, IL-35, TGF-β; reduction in the expression levels of IL-1β, IL-6, TBX21, and FOXP3, FoxP3, IL-10, IL-35, and TGF-β as well as upregulation of the frequency of Treg cells, reduction in the number of Th17 cells, Th17 cell-related cytokines levels, and downregulation of Th17 cell-related factors (54–59).